Loette must not be used in women with any of the following conditions: Deep vein thrombosis (current or history).
Thromboembolism (current or history).
Hepatic adenomas or carcinomas, or active liver disease, as long as liver function has not returned to normal.
Known or suspected carcinoma of the breast, or other known or suspected estrogen dependent neoplasia.
Disorders of lipometabolism.
Thrombogenic rhythm disorders and thrombogenic valvulopathies.
Sickle cell anemia.
Diabetes with vascular involvement.
Undiagnosed vaginal bleeding.
Known or suspected pregnancy.
Hypersensitivity to any of the components of Loette.
Cerebrovascular or coronary artery disease.
Hereditary or acquired thrombophilias.
Headache with focal neurological symptoms, such as aura.
Pancreatitis associated with severe hypertriglyceridemia (current or history).
COCs are contraindicated for concomitant use with certain anti-viral hepatitis C virus (HCV) medicinal products such as ombitasvir, paritaprevir, ritonavir and dasabuvir (see Hepatic neoplasia/liver disease/hepatitis C under Warnings and Interactions).
REASONS FOR THE IMMEDIATE DISCONTINUATION OF LOETTE: Occurrence for the first time of migrainous headaches or the more frequent occurrence of unusually severe headaches.
Acute disturbances of vision, hearing, or speech.
First symptoms of thrombophlebitis or thromboembolism (e.g., unusual pain in or swelling of the legs, stabbing pain on breathing, or coughing for no apparent reason).
Feeling of pain or tightness in the chest.
Six weeks before planned operations or during prolonged periods of immobilization.
Development of jaundice (cholestasis), hepatitis, or generalized pruritus.
Increase in epileptic seizures.
Significant rise in blood pressure.
Onset of severe clinical depression.
Severe upper abdominal pain or liver enlargement.